Regional overviews

celebrating 20 years Developing Europe & CIS

STATISTICS  
Number of products launched: 0 (2017: 1)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years USD4 million
3 – 5 years USD0 million
Number of product recalls: 0 (2017: Nil)
Average staff turnover: 14,5% (2017: 13,7%)
Number of work-related fatalities: 0 (2017: Nil)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio. The Anaesthetics portfolio is anticipated to become a significant contributor in this region.

KEY COUNTRIES

Czech Republic, Poland, Romania, Russia, Slovakia

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Regional Brands 64 80 (20)
Anaesthetics 434 307 41
Thrombosis 1 876 1 760 7
High Potency & Cytotoxics 406 464 (13)
Total 2 780 2 611 6
 
  • Injectable anticoagulants across Developing Europe & CIS grew 3,3% by volume. Over the same period, volumes in Russia grew 9,7%.
  • The value growth of the Anaesthetics category for the region was 6,6% for the year ended 30 May 2018.
Source: May 2018 IMS